Brief: Abbisko Cayman Unit's CSF-1R Inhibitor Gets Phase III Trial Approval From China's NMPA
24/10/2022 23:15
Oct 25 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* CSF-1R INHIBITOR ABSK021 OF UNIT GRANTED PHASE III
CLINICAL
TRIAL APPROVAL BY CHINA'S NMPA
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly